Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) Director Ra Capital Management, L.P. acquired 1,200,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was purchased at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the acquisition, the director now directly owns 9,317,246 shares in the company, valued at approximately $416,946,758.50. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Janux Therapeutics Stock Up 4.6 %
Shares of NASDAQ JANX opened at $52.80 on Wednesday. The business has a 50-day moving average price of $46.09 and a 200 day moving average price of $45.63. The stock has a market cap of $2.74 billion, a PE ratio of -43.28 and a beta of 3.54. Janux Therapeutics, Inc. has a 52-week low of $5.65 and a 52-week high of $65.60.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm’s quarterly revenue was up 709.1% on a year-over-year basis. Sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on JANX
Institutional Trading of Janux Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Summit Securities Group LLC purchased a new stake in Janux Therapeutics during the 2nd quarter valued at approximately $29,000. Amalgamated Bank raised its stake in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in Janux Therapeutics during the 2nd quarter valued at approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $151,000. Finally, AQR Capital Management LLC purchased a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $215,000. 75.39% of the stock is owned by hedge funds and other institutional investors.
Janux Therapeutics Company Profile
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
See Also
- Five stocks we like better than Janux Therapeutics
- How to buy stock: A step-by-step guide for beginners
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.